Skip to content 
Search

Latest Stories

Innovative gene therapy gets approval for two blood disorders

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorisation for Casgevy to be used to treat sickle cell disease and beta thalassemia

Innovative gene therapy gets approval for two blood disorders

The UK's medicines regulator has given approval for a groundbreaking gene therapy, Casgevy, to potentially treat two hereditary blood disorders.

This innovative treatment, designed for sickle cell disease and beta thalassemia, marks a significant milestone as the first licensed therapy using the CRISPR gene-editing tool, pioneered by Nobel Prize-winning inventors in 2020.


The tool that “edits” the gene that causes the blood disorders is also called the “genetic scissors,” The Guardian reported.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorisation for Casgevy to be used to treat sickle cell disease and beta thalassemia.

Sickle cell disease and beta thalassemia stem from genetic flaws affecting haemoglobin genes, critical for oxygen transportation by red blood cells throughout the body.

The developers of Casgevy envision that this pioneering treatment could alleviate the pain, infections, and anaemia associated with sickle cell disease, as well as address the severe anaemia commonly seen in individuals with beta thalassemia.

Approximately 15,000 individuals in the UK, predominantly of African or Caribbean descent, are living with sickle cell disease. Additionally, around 1,000 individuals, primarily from Mediterranean, south Asian, southeast Asian, and Middle Eastern backgrounds, are affected by beta thalassemia and require regular blood transfusions to manage their anemia.

People from south Asian communities are more likely to have conditions such as Thalassemia which also mean they need regular transfusions.

Experts in the field hold hope that Casgevy could offer a definitive cure, eliminating the need for bone marrow transplants, which have been the sole treatment option to date, despite the risk of donor marrow rejection.

The Sickle Cell Society hailed the MHRA's decision as a "historic moment for the sickle cell community," expressing renewed hope and optimism.

The charity further stated that the approval of Casgevy, developed by Vertex Pharmaceuticals, empowers the NHS to adopt it as a revolutionary therapeutic intervention for individuals battling this condition, characterised by chronic anemia, recurring episodes of excruciating pain necessitating hospitalisation, organ damage, an increased risk of stroke, and premature mortality.

Sickle cell disease and beta thalassemia are genetic disorders, or inherited conditions, arising from errors in the genes responsible for hemoglobin, a protein that enables red blood cells to transport oxygen throughout the body. Both conditions can be fatal.

The MHRA said, “Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin. To do this, stem cells are taken out of bone marrow, edited in a laboratory and then infused back into the patient, after which the results have the potential to be lifelong.”

During this process, laboratory personnel utilise the "genetic scissors" technique to modify, or cut, the DNA of the patient's bone marrow cells, prior to their reintroduction via infusion.

The MHRA has indicated that patients may require a minimum month-long hospital stay while the treated cells establish themselves in the bone marrow and begin production of red blood cells containing the stable form of hemoglobin.

In a clinical trial evaluating Casgevy for sickle cell disease, 28 out of the 29 patients remained free from major pain episodes, which can necessitate hospitalisation, for at least a year following treatment.

Among the 42 beta-thalassemia patients who participated in the clinical trial, 39 did not require any red blood cell transfusions for a minimum of 12 months following Casgevy treatment.

Consultant haematologist at University College hospital London and expert in sickle cell disease, Dr Sara Trompeter said, “Whilst curative treatments may not be suitable for all, gene therapy offers a real chance of cure for those who are not eligible for bone marrow transplants and so we are delighted that it has been approved by MHRA.”

More For You

Barbie with type 1 diabetes

This is also part of Mattel’s mission to extend the boundaries of imaginative play

Mattel

Mattel introduces first Barbie doll with type 1 diabetes to promote inclusion

Highlights

  • Mattel launches new Barbie with type 1 diabetes
  • The doll features a glucose monitor, insulin pump and CGM app
  • Created in collaboration with type 1 diabetes charity Breakthrough T1D
  • Part of Mattel’s broader push for inclusivity and representation in toys

Barbie with type 1 diabetes joins inclusive fashionistas range

Mattel has launched its first diabetes Barbie doll, designed to represent children with type 1 diabetes and promote greater inclusivity in children’s toys.

The new addition to the Barbie Fashionistas line comes with realistic medical features including a continuous glucose monitor (CGM) on her arm, secured with heart-shaped medical tape, and an insulin pump to help manage her blood sugar levels. She also carries a smartphone with a CGM app to monitor glucose throughout the day, and a bag large enough to store snacks and other essentials.

Keep ReadingShow less
Schiaparelli exhibition UK

Italian-born French fashion designer Elsa Schiaparelli

Getty Images

V&A announces UK’s first Schiaparelli exhibition as Natasha Poonawalla’s Met Gala looks make a comeback

“In difficult times fashion is always outrageous.” – Elsa Schiaparelli.

The Victoria & Albert Museum has announced its first ever UK exhibition dedicated to Elsa Schiaparelli, the visionary designer who blurred the boundaries between fashion, art and performance. Titled Schiaparelli: Fashion Becomes Art, it runs from 21 March to 1 November 2026 in the Sainsbury Gallery and will draw on the V&A’s status as home to Britain’s National Collection of Dress and its foremost collection of Schiaparelli garments.

Keep ReadingShow less
Martin Lewis warns shoppers

Lewis clarifies legal rights for online and in-store purchases

iStock

Martin Lewis warns shoppers about misleading return policies at 30 UK retailers

Highlights

  • Martin Lewis flags incorrect return rights information on 30 retail websites
  • Retailers include New Look, The Range, and Selfridges
  • Lewis clarifies legal rights for online and in-store purchases
  • Trading Standards to be alerted following MoneySavingExpert.com investigation

Martin Lewis highlights return rights confusion

Money-saving expert Martin Lewis has issued a warning to UK consumers after uncovering misleading returns information on the websites of 30 major retailers, including New Look, The Range, and Selfridges.

Speaking on ITV1's Good Morning Britain, Lewis explained that several retailers are presenting incorrect information about return rights for online shoppers — in some cases, underplaying the legal protections customers are entitled to.

Keep ReadingShow less
Gemma Collins Instagram ban

Collins accepted the findings of the ASA’s investigation

Getty Images

Gemma Collins’ Instagram post banned over weight-loss drug promotion

Highlights

  • Instagram post by Gemma Collins promoting Yazen weight-loss service banned
  • ASA rules it breached regulations on promoting prescription-only medication
  • Eight other weight-loss ads also banned in regulatory crackdown

ASA bans Collins' Instagram advert

An Instagram post by TV personality Gemma Collins promoting a weight-loss drug and digital service has been banned by the UK’s advertising watchdog for breaching regulations around prescription-only medicines.

Collins had shared a promotional video on 6 January 2025, stating: “I’m starting this year two sizes down, thanks to Yazen’s weight loss app and medication.” The Advertising Standards Authority (ASA) ruled that the post unlawfully promoted prescription-only medication to the public.

Keep ReadingShow less
5 secret beaches

Barafundle Bay, Pembrokeshire, Wales

iStock

5 secret beaches in the UK that feel like the tropics

Key points

  • Discover hidden UK beaches with turquoise waters and golden sands
  • Ideal for summer staycations without the cost of long-haul travel
  • Includes lesser-known spots in Wales, Scotland, Cornwall, and more
  • Perfect for quiet escapes, coastal walks, and Instagram-worthy views

Escape to paradise – no passport required

Think you need to fly halfway across the world for clear blue water and white sand? Think again. The UK is home to a surprising number of secluded beaches that look straight out of the Caribbean – without the crowds or jet lag. From hidden coves in Cornwall to windswept bays in the Scottish Highlands, here are some of the most tropical-looking beaches on British soil.

1. Barafundle Bay, Pembrokeshire, Wales

Often dubbed the UK’s answer to the Caribbean, this National Trust-owned gem boasts golden sand, crystal-clear waters, and dramatic cliffs. Accessed by a half-mile walk from Stackpole Quay, it remains blissfully untouched by development.

Keep ReadingShow less